VCEL News and Press, Vericel Corporation From 08/02/23

2023-08-02 15:04:02 ET Vericel Corporation (VCEL) Q2 2023 Earnings Conference Call August 2, 2023, 08:30 AM ET Company Participants Eric Burns - VP, Finance and IR Nick Colangelo - President and CEO Joe Mara - CFO Conference Call Participants Ryan Zim...

2023-08-02 07:58:24 ET Vericel press release ( NASDAQ: VCEL ): Q2 GAAP EPS of -$0.11 beats by $0.04 . Revenue of $45.9M (+23.9% Y/Y) beats by $3.77M . Non-GAAP adjusted EBITDA of $4.4 million. Operating cash flow of $10.2 million. As of June 30, 2023, t...

Record Second Quarter Total Revenue of $45.9 Million, Representing 24% Growth versus Prior Year MACI Revenue Growth of 27% to $36.3 Million Epicel Revenue Growth of 17% to $9.6 Million Full-Year 2023 Revenue Guidance Raised to $190-197 Million Conference Call Tod...

2023-08-01 13:23:06 ET Vericel ( NASDAQ: VCEL ) is scheduled to announce Q2 earnings results on Wednesday, August 2nd, before market open. The consensus EPS Estimate is -$0.15 (vs. -$0.19 last year) and the consensus Revenue Estimate is $42.13M (+13.7% Y/Y). Over the l...

CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023. Vericel’s ...

2023-07-09 11:00:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Editor’s note: “A Golden Ticket to Profiting From ‘Hidden’ Bull Markets ” was previously published in January 2023 . It has since been updated t...

2023-06-27 22:57:44 ET Summary Vericel Corporation demonstrates consistent growth in its core product lines, including MACI for cartilage repair and Epicel for severe burn treatment, with significant competitive advantages and barriers to entry. The company is expanding its market...

2023-05-30 15:01:52 ET MediWound Ltd. ( NASDAQ: MDWD ), an Israel-based developer of enzymatic therapeutics for tissue repair, lost ~7% Tuesday after announcing its Q1 2023 financials that failed to meet Street forecasts. The company reported $3.8M in revenue for the qua...

Shares of Vericel Corporation (NASDAQ: VCEL) traded at a new 52-week high today and are currently trading at $35.53. So far today, approximately 50,848 shares have been exchanged, as compared to an average 30-day volume of 250.26k shares. Vericel Corporation, a commercial-stage biopharmaceuti...

2023-05-10 11:34:08 ET Vericel Corporation (VCEL) Q1 2023 Earnings Conference Call May 10, 2023, 8:30 AM ET Company Participants Eric Burns - Vice President, Finance and Investor Relations Nick Colangelo - President and CEO Joe Mara - Chief Financial Officer ...